Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Wilson Therapeutics logo — Innovative pathways to treat rare conditions and enhance pat...

Wilson Therapeutics

Innovative pathways to treat rare conditions and enhance patient lives

Founded 2012 Post Ipo Equity Total: $284.00M Biotechnology, Health Care +1

General Information

Company Name Wilson Therapeutics
Founded Year 2012
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when Wilson Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Wilson Therapeutics

Wilson Therapeutics is a Stockholm-based biopharmaceutical company founded in 2012. The company's slogan, "Innovative pathways to treat rare conditions and enhance patient lives," reflects its focus on creating advanced treatments for individuals with rare conditions such as Wilson Disease. Their premier product, Decuprate®, is currently undergoing evaluation in a Phase II clinical study for this indication. The company recently received a kr244.00M investment in Post-IPO Equity on 08 December 2017. With a strong emphasis on Biotechnology, Health Care, and Health and Wellness industries, Wilson Therapeutics is poised to make a significant impact in the field of rare disease treatment.

Taxonomy: biopharmaceutical company, rare diseases, Wilson Disease, Stockholm, clinical study, patient treatments, Phase II, new therapies, Decuprate®, novel solutions, patient lives, innovative treatments

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 08 Dec 2017
Series B •••••• 4
Investor Investor Investor
•••• •••• 		16 Apr 2014

Wilson Therapeutics Alternatives & Competitors

Wilson Therapeutics vs
Orphalan
Orphalan France

At Orphalan we strive to develop rare disease treatments to improve patients lives.

111 employees
Health Care
Wilson Therapeutics vs
Aceragen
Aceragen United States

Aceragen is a rare disease company striving to restore a better life for patients and families.

Private Equity
2 employees
Biotechnology, Health Care
Wilson Therapeutics vs
HemWell MD
HemWell MD United States

The very best in non-surgical hemorrhoid treatments - quick, simple, and painless, treating all grad...

4 employees
Health Care, Medical Devices

FAQ About Wilson Therapeutics

Innovative pathways to treat rare conditions and enhance patient lives
Wilson Therapeutics was founded in 2012.
Wilson Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Wilson Therapeutics has completed 2 funding rounds, raising a total of $284.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Wilson Therapeutics include Orphalan, Aceragen, HemWell MD, Probably Genetic, Tern Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Wilson Therapeutics and Orphalan are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Wilson Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy